The latest immunotherapy news and developments
Phase 2 trial data shows durvalumab immunotherapy with standard chemotherapy improved survival in malignant pleural mesothelioma
The PrE0505 phase 2 clinical trial results are published in the journal Nature Medicine. The study evaluated the…